评估细胞介导免疫和循环免疫复合物作为癌症患者的预后指标。

Evaluation of cell-mediated immunity and circulating immune complexes as prognostic indicators in cancer patients.

作者信息

Aziz M, Akhtar S, Malik A

机构信息

Department of Pathology, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh, India.

出版信息

Cancer Detect Prev. 1998;22(2):87-99. doi: 10.1046/j.1525-1500.1998.00001.x.

DOI:10.1046/j.1525-1500.1998.00001.x

PMID:9544429

Abstract

Cell-mediated immunity (CMI) and circulating immune complexes (CIC) were estimated in 55 cancer patients and 25 control volunteers to evaluate their prognostic significance. Cancer patients comprised head and neck cancer (11), breast cancer (13), gastrointestinal cancer (10), genitourinary cancer (11), and lymphomas and sarcomas (10). CMI was tested in vitro by early rosette-forming cells (ARFC) and total rosette-forming cell (TRFC) counts. ARFC count in control group was 758.1 +/- 78.09 cells/cumm. In advancing clinical stages of cancer (I-IV), ARFC counts were decreased (i.e., 601.12 +/- 74.96 [p < 0.01]; 494.8 +/- 71.83 [p < 0.001]; 432.44 +/- 36.05 [p < 0.001], and 438.55 +/- 69.99 [p < 0.001] cells/cumm, respectively). TRFC count in control group was 1029 +/- 88.39 cells/cumm. In cancer stages I through IV, these counts decreased significantly (i.e., 699.63 +/- 66.24; 597.55 +/- 82.9; 505.11 +/- 52.56; and 501.55 +/- 69.99 cells/cumm, respectively [p < 0.001]. Dinitrochlorobenzene cutaneous reactivity in vivo was 100% positive in control group, 62.5% positive in cancer stage I, 5% positive in stage II, and negative in stages III and IV. CIC of intermediate size were estimated by polyethylene glycol precipitation (PEG pptn) technique, which detects CIC in the ratio of 2:1 (Ag2Ab). Mean PEG index in control group was 39.5 +/- 4.65; sequential increase in CIC was observed in advancing clinical stages of cancer (I-IV)(i.e., 49 +/- 7.03 [p < 0.01]; 75.38 +/- 44.01 [p < 0.001]; 93.38 +/- 44.57 [p < 0.001]; and 216.00 +/- 147.05 [p < 0.001], respectively). Latex agglutination inhibition (LAI) titer was done to detect CIC as small as 8s, which constitute the opposite polar end of CIC spectrum. LAI titers in control group were nil. However, LAI titers in cancer stages I through IV were 1 +/- 2.64; 8.6 +/- 5.6 (p < 0.001); 12.00 +/- 8.11 (p < 0.001); and 25.77 +/- 9.06 (p < 0.001), respectively. Decrease in CMI and subsequent increase in CIC indicate unfavorable prognosis in cancer patients, and also precede clinical manifestation of increased tumor mass in vivo.

摘要

对55例癌症患者和25名对照志愿者的细胞介导免疫（CMI）和循环免疫复合物（CIC）进行评估，以评价其预后意义。癌症患者包括头颈癌（11例）、乳腺癌（13例）、胃肠道癌（10例）、泌尿生殖系统癌（11例）以及淋巴瘤和肉瘤（10例）。通过早期玫瑰花结形成细胞（ARFC）计数和总玫瑰花结形成细胞（TRFC）计数在体外检测CMI。对照组的ARFC计数为758.1±78.09个细胞/立方毫米。在癌症进展期（I - IV期），ARFC计数下降（即分别为601.12±74.96 [p < 0.01]；494.8±71.83 [p < 0.001]；432.44±36.05 [p < 0.001]和438.55±69.99 [p < 0.001]个细胞/立方毫米）。对照组的TRFC计数为1029±88.39个细胞/立方毫米。在癌症I期至IV期，这些计数显著下降（即分别为699.63±66.24；597.55±82.9；505.11±52.56；和501.55±69.99个细胞/立方毫米 [p < 0.001]）。二硝基氯苯皮肤体内反应性在对照组中100%呈阳性，在癌症I期为62.5%呈阳性，II期为5%呈阳性，III期和IV期为阴性。通过聚乙二醇沉淀（PEG pptn）技术估计中等大小的CIC，该技术以2:1（Ag2Ab）的比例检测CIC。对照组的平均PEG指数为39.5±4.65；在癌症进展期（I - IV期）观察到CIC依次增加（即分别为49±7.03 [p < 0.01]；75.38±44.01 [p < 0.001]；93.38±44.57 [p < 0.001]；和216.00±147.05 [p < 0.001]）。进行乳胶凝集抑制（LAI）滴度检测以检测小至8s的CIC，其构成CIC谱的相反极性末端。对照组的LAI滴度为零。然而，癌症I期至IV期的LAI滴度分别为1±2.64；8.6±5.6（p < 0.001）；12.00±8.11（p < 0.001）；和25.77±9.06（p < 0.001）。CMI降低以及随后CIC增加表明癌症患者预后不良，并且在体内肿瘤块增加的临床表现之前出现。